APA (7th ed.) Citation

M, M., O, S., JJ, O., RM, K., Z, S., EI, H., . . . DS, C. (2025). Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer. European urology oncology, 8(4), 1087. https://doi.org/10.1016/j.euo.2025.06.004

Chicago Style (17th ed.) Citation

M, Muniz, et al. "Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer." European Urology Oncology 8, no. 4 (2025): 1087. https://doi.org/10.1016/j.euo.2025.06.004.

MLA (9th ed.) Citation

M, Muniz, et al. "Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer." European Urology Oncology, vol. 8, no. 4, 2025, p. 1087, https://doi.org/10.1016/j.euo.2025.06.004.